Bevacizumab in combination with 5-fluorouracil plus folinic acid,
with or without irinotecan, is not recommended for people with
metastatic colorectal cancer who have not been treated before.

Cetuximab in combination with irinotecan is not recommended for
people with metastatic colorectal cancer who have had previous
treatment for the cancer that also included irinotecan.

Consultants should not stop prescribing bevacizumab or cetuximab
for people who were already taking it when the guidance was
issued. These patients should be able to carry on taking bevacizumab
or cetuximab until they and their consultants decide that it is the
right time to stop treatment.